louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03928990: Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life
Official title: Assesment of Physical Activity Level of Patients With Multiple Sclerosis: From Laboratory to Real Life
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Multiple Sclerosis
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2019-04-26
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aims to assess the feasibility of a protocol determining individual moderate-to-vigorous physical activity (MVPA) thresholds, among multiple sclerosis patients, in routine medical practice.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18 to 80 years old
* Multiple sclerosis according to McDonald criteria ;
* Expanded Disability Status Scale (EDSS) between 0 and 6.5 ;
* Patient able to move with or without mechanical assistance.

Exclusion Criteria:

* Deterioration of neurological symptomatology within 60 day before enrollment ;
* Changes brought to the multiple sclerosis treatment within 6 months before enrollment ;
* Introduction of a treatment acting on spasticity or fatigue within 30 day before enrollment
* Changes brought to reeducation protocol throughout the duration of the study
* Patient unable to provide an effort equivalent to 3 times the resting metabolic value = 3 Metabolic Equivalent of Task (METs).

Primary outcomes:
measure: Patient's feeling
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
Study officials:
References:
Clinical trial NCT01384890: Feasibility of VMAT and CBCT for Head and Neck Carcinomas
Official title: Feasibility of Volumetric Modulated Arc Therapy and Cone-Beam Computed Tomography for Head and Neck Carinomas: Analysis of Clinical Throughput and Patient Reported Outcomes.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Head and Neck Carcinoma
Lead sponsor: British Columbia Cancer Agency
Sponsor class: OTHER
First posted: 2011-06-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This will be a prospective longitudinal study describing clinical throughput metrics and patient reported quality of life outcome measures for patients undergoing Volumetric modulated arc therapy (VMAT) with and without Cone-beam computed tomography (CBCT) for head and neck carcinoma at the British Columbia Cancer Agency.

1. VMAT for the treatment of patients with HNC will provide opportunities for image-guided radiotherapy using CBCT online correction to reduce systematic and random error.
2. Analysis of patient reported quality of life outcomes during VMAT, with and without CBCT acquisition, will be hypothesis generating.


Eligibility criteria: Inclusion Criteria:

* age greater than 18 years
* undergoing radical radiation therapy for head and neck carcinoma at the BC Cancer Agency

Exclusion Criteria:

* treatment being offered is not for curative intent
* patient has received previous radiation for head and neck cancer
* patient has systemic lupus erythematosis or scleroderma
* patients has other autoimmune connective tissue disorders

Primary outcomes:
measure: Clinical efficiency for volumetric modulated arc therapy (VMAT) delivery
timeFrame: After patient treated
measure: Position verification
timeFrame: After patient treated
Secondary outcomes:
measure: Quality of life
timeFrame: No time frame (ongoing)
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Cancer Agency - Vancouver Centre
state: British Columbia
Study officials:
affiliation: British Columbia Cancer Agency
name: Jonn Wu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01734590: Effect of Different Flour Compositions in a Carbohydrate-based Food on Rate of Exogenous Glucose Appearance in Blood
Official title: The Effect of Different Flour Compositions in a Carbohydrate-based Food on Rate of Exogenous Glucose Appearance in Blood.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Flour,
carbohydrate,
digestibility
subjects
Lead sponsor: Unilever R&D
Sponsor class: INDUSTRY
First posted: 2012-11-27
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Exploratory study with double-blind, randomized, placebo-controlled, full cross-over design.

The main objective is to identify one or two flour compositions in a carbohydrate-based food that produce a significant difference (alpha =0.2) in the time to reach 50% of cumulative absorption of exogenous glucose compared to the control.

Detailed description: Twelve volunteers will participate in the study; each person will be studied on three different occasions at least one week apart, consuming the three different test products in a randomized order. Test products are carbohydrate-based food made from different flour mixes differing in their expected rate of intestinal starch digestion. The products are labeled with 13C starch.

Eligibility criteria: * healthy males
* Age at start of the study ≥18 and ≤ 50 years
* Not smoking
* Body mass index (BMI) ≥ 20 and ≤ 28 kg/m2
* Fasting blood glucose value of volunteer is ≥ 3.4 and ≤ 6.1 mmol/litre (i.e. 62-110 mg/dl) at screening

Primary outcomes:
measure: Rate of appearance of exogenous glucose (RaE) based on the dual isotope technique.
timeFrame: Measured during 360 min for 3 periods
Secondary outcomes:
measure: Total blood glucose and insulin
timeFrame: Measured during 360 min for 3 periods
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: QPS
state: Hanzeplein 1
Study officials:
affiliation: QPS Netherlands BV
name: Khalid Abd-Elaziz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06544590: Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
Official title: Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Meniere Disease
Keywords: Meniere Disease, taVNS, case-control, retrospective
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2024-08-09
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Meniere Disease is a clinical condition defined by hearing loss, tinnitus, and aural fullness symptoms, there are currently no any medications approved for its treatment. The aim of study is to determine taVNS as an adjunctive therapy could relieve symptoms in treatment period and follow-up period in patients with Meniere disease. Outcome measures include vHIT, the Caloric Test, THI, DHI, Pure Tone Auditory, and VAS.

Brief summary: Objective: To evaluate the effect of Transcutaneous auricular vagus nerve stimulation for the patients Meniere disease.

Methods: We enrolled 231 patients at Beijing TongRen Hospital. All treatments were self-administered by the patients at home after training at the hospital. Patients completed questionnaires at baseline, 3 months, 6 months, and 12 months. Video head impulse test (VHIT), the caloric test, Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI), Pure Tone Audiometry, and visual scale of ear stuffiness to evaluate the therapeutic effects. A difference of P \< 0.05 was considered statistically significant.


Eligibility criteria: Inclusion Criteria:

* 1. Age \>=18 and Age \<=65. 2. Clinical diagnosis of meniere disease.

Exclusion Criteria:

1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases.
2. History of Otorhinolaryngology surgery.
3. Pregnant or lactating women.

Primary outcomes:
measure: Video head impulse test (VHIT)
timeFrame: Baseline, month 3, 6 and 12
Secondary outcomes:
measure: The caloric test
timeFrame: Baseline, month 3, 6 and 12
measure: Tinnitus Handicap Inventory (THI)
timeFrame: Baseline, month 3, 6 and 12
measure: Dizziness Handicap Inventory (DHI)
timeFrame: Baseline, month 3, 6 and 12
measure: Pure tone thresholds
timeFrame: Baseline, month 3, 6 and 12
measure: Visual analogue scale (VAS)
timeFrame: Baseline, month 3, 6 and 12
Other outcomes:
Locations:
city: Beijing
country: China
facility: China Beijing TongRen Hospital, Capital Medical University Beijing, China
state: Beijing
Study officials:
References:
Clinical trial NCT00004390: Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain
Herpes Zoster
Keywords: disease-related problem/condition
herpes zoster infection
herpesvirus infection
immunologic disorders and infectious disorders
pain
rare disease
viral infection
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
name: Johns Hopkins University
First posted: 1999-10-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: OBJECTIVES: I. Determine whether opioid (morphine) treatment results in better management of pain than treatment with tricyclic antidepressant (nortriptyline).

II. Assess the effects the two treatments have on affective and cognitive functions.

III. Determine whether the presence of psychiatric comorbidity, particularly depression, can predict the outcome of the two treatments.

Detailed description: PROTOCOL OUTLINE: This is a randomized, double blind, crossover study. Patients are stratified by the duration of pain (greater than 1 year or no greater than 1 year) and the presence or absence of major depression.

Patients are randomized into 6 treatment order groups. Patients start with nortriptyline, morphine, or placebo, taken orally every day. If patients are unable to tolerate nortriptyline or morphine, they will receive desipramine or methadone instead.

A drug titration period lasting 3 weeks is ensued for administration of the first drug treatment. The goal of this titration period is to gradually increase the dose of the drug to obtain maximal analgesic efficacy. Drug dosage is maintained for a period of 3 weeks. The drug dosage is tapered off and followed by a drug free period of 1 week.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

* Diagnostically confirmed postherpetic neuralgia for at least 3 months following a segmental herpes zoster eruption

--Prior/Concurrent Therapy--

* Other: No concurrent monoamine oxidase inhibitors

--Patient Characteristics--

* Life expectancy: At least 6 months
* Cardiovascular: No second degree or complete heart blockage No myocardial infarction in the last 3 months
* Pulmonary: No severe pulmonary disease
* Other: No history of substance abuse No history of dementia No history of encephalopathy No severe depression that precludes withdrawal from antidepressants Not pregnant No angle-closure glaucoma No AIDS related disease complex No terminal disease with life expectancy of less that 6 months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Johns Hopkins University
name: Srinivasa N. Raja
role: STUDY_CHAIR
References:
Clinical trial NCT00785590: Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.
Official title: Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hygiene
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-11-05
Enrollment: 26
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd PHDETINLYN Sweet Flower.


Eligibility criteria: Inclusion criteria:

* Phototype Skin II and III;
* Integral skin test in the region;
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

* Lactation or gestation
* Use of Antiinflammatory and/or immunosuppression drugs 15 days before the selection;
* Diseases which can cause immunity decrease, such as HIV, diabetes;
* Use of drug photosensitizer;
* History of sensitivity or irritation for topic products;
* Active cutaneous disease which can change the study results;
* History of photodermatosis active;
* Family or personal antecedent of cutaneous photoinduced neoplasias;
* Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium;
* Intense solar exposure in the study area;
* Use of new drugs or cosmetics during the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale
timeFrame: Throughout the study
measure: The sensibility will be evaluated according to the skin type.
timeFrame: Throughout the study
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Jaderson Lima
role: STUDY_DIRECTOR
References:
Clinical trial NCT01301690: Development of a Novel Methodology Using BMVC Staining as an Assistance to Cancer Cytological Diagnosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neck Mass
Keywords: neck mass
ultrasound
FNA
BMVC
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2011-02-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We propose to collect consecutive patients (age range from 18 to 90 years old) with neck lumps, receiving sonographic examination and FNA cytologic study.

Brief summary: 3,6-bis(1-methyl-4-vinylpyridinium) carbazole diiodide (BMVC) is an inorganic chemical compound (Figure1). The uptake of BMVC in cancer cells and normal cells are different. Recently, a simple handheld device (Figure1) based on the fluorescence analysis of stained cells was established to instantly differentiate cancer cells from normal cells. The investigators want to quantitatively measure the fluorescence expression of BMVC in normal and cancer cells and explore the usefulness of this staining in head and neck lumps.


Eligibility criteria: Inclusion Criteria:

* patients (age range from 18 to 90 years old) with neck lumps, receiving sonographic examination and FNA cytologic study.

Exclusion Criteria:

* No cytology data

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Otolaryngology Far Eastern Memorial Hospital
Study officials:
affiliation: Department of Otolaryngology Far Eastern Memorial Hospital, Taipei, Taiwan
name: Li-Jen Liao, MD
role: STUDY_DIRECTOR
References:
citation: Liao LJ, Kang CC, Jan IS, Chen HC, Wang CL, Lou PJ, Chang TC. Improved diagnostic accuracy of malignant neck lumps by a simple BMVC staining assay. Analyst. 2009 Apr;134(4):708-11. doi: 10.1039/b814417f. Epub 2009 Jan 24.
Clinical trial NCT01326390: Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma
Official title: Impact of C-arm CT in Patients With Decreased Renal Function Undergoing Transhepatic Arterial Chemoembolization (TACE) for the Treatment of Hepato-Cellular Carcinoma
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Kidney (Renal Cell) Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2011-03-30
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients we are seeking will already have been scheduled to undergo liver Transhepatic arterial chemoembolizationWorld Health Organization treatment using C-arm CT as the imaging guidance (with limited Digital Subtraction angiography as needed).

Brief summary: Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.


Eligibility criteria: Inclusion Criteria:

1. Patients must be affected by HCC
2. Patients must have diminished renal function (GFR\<60 ml/min/1.73m\^2)
3. Patients must be 18 years old or older
4. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.
5. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Subjects under the age of 18
2. Patients currently on dialysis
3. Pregnant women

Primary outcomes:
measure: Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Nishita N. Kothary
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06257290: The Role of Platelet TLRs in Platelet Activation During VTE
Official title: The Role of Platelet TLRs in Platelet Activation During VTE
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Venous Thromboembolism
Keywords: venous thromboembolism
VTE
sequelae
immunothrombosis
platelets
inflammatory receptors
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2024-02-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Venous ThromboEmbolic (VTE) patients

Brief summary: Venous thromboembolic disease (VTE) is a frequent and potentially serious pathology. Therapeutic management has improved considerably over the last few decades, enabling the application of codified management in line with the recently updated French management recommendations.

One of the main remaining difficulties concerns VTE sequelae, mainly post-thrombotic syndrome after deep vein thrombosis, and post-pulmonary embolism syndrome after pulmonary embolism. The mechanisms leading to the absence of complete repermeabilization of vessels affected by Venous thromboembolic disease (VTE) are still poorly understood.

The concept of immunothrombosis, closely associating immunity, inflammation and thrombosis, could (in part) explain the appearance of these sequelae. Platelets appear to play a key role in the onset of sequelae: Platelets are known to be involved both in the onset of a VTE episode and in the inflammatory response. This involvement is illustrated by the expression of inflammatory receptors such as TLR (toll-like receptor) 2 and TLR4.

Th aim to investigate the role of platelets in the occurrence of sequelae, mainly via their role in the inflammatory response, in Venous thromboembolic disease (VTE) patients.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with Venous ThromboEmbolic (VTE) / Proximal Deep vein thrombosis (DVT) of the lower limb and/or pulmonary embolism ≤ 72heures
* Patients are 18 years of age or older at diagnosis.
* Patients received informed written consent
* Patients benefiting from social security coverage

Exclusion Criteria:

* Diagnosis of Venous ThromboEmbolic (VTE) more than 72 hours old
* Isolated sub-segmental pulmonary embolism
* Patients on antiplatelet agents
* Patients on non-steroidal anti-inflammatory drugs (NSAIDs)
* Life expectancy \> 3 months

Primary outcomes:
measure: expression of TLR2/ TRL4
timeFrame: at day1 and at 6 months
Secondary outcomes:
measure: Analysis of characteristic soluble profile of the inflammatory role of platelets
timeFrame: at day1 and at 6 months
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: Chu St-Etienne
Study officials:
References:
Clinical trial NCT05863390: Effectiveness of McKenzie and Trochanteric Belt With CT Therapy to Reduce Pain and Dysfunction of SI Joint
Official title: Effectiveness of McKenzie Exercises and Trochanteric Belt With Conventional Physical Therapy to Reduce Pain and Dysfunction of SI Joint in Pregnant Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sacroiliac Joint Dysfunction
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2023-05-18
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To determine the effectiveness of McKenzie exercises and trochanteric belt with conventional physical therapy to reduce pain and dysfunction of Sacroiliac joint (SIJ) in pregnant women

Detailed description: to findout the effectiveness of exercises in pregnant women

Eligibility criteria: Inclusion Criteria:

* Pregnant patients with sacroiliac joint pain are included and participant patients with age group 18- to 35
* low back pain due to sacroiliac joint who suffer from sever pain during sitting and during positioning change when stand from sitting position are included

Exclusion Criteria:

* Patients with age group of below 18 years and above 35 years
* Patients with disease of coagulopathy
* systemic infection
* skin infection over sacroiliac joint patients with history of allergies to injected medications.
* Patients with psoriasis
* inflammatory bowel disease
* peripheral arthritis
* Women with UTI complications are excluded.
* Women with respiratory issues are also excluded

Primary outcomes:
measure: feature of Visual analogue scale to check pain and feature PSFS to check Movement of joints
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: • General Hospital. • Chaudhary Muhammad Akram Teaching and Research Hospital, University of Lahore Teaching Hospital, Shadman Medical Center, Services Hospital, Bahria International Hospital
Study officials:
affiliation: Superior Uni
name: Abdul Wahab
role: STUDY_CHAIR
References: